Inspira Technologies, a medical technology firm focused on the respiratory treatment arena, has received US patent approval for VORTX, an orbiting blood oxygenation delivery system.
VORTX, a core technology of the INSPIRA ART500 device, is designed to oxygenate blood without fibre membranes and transform the medical landscape.
The first-ever US patent approval included 16 claims by Inspira that were found to be new.
The patient’s blood cells suffer significant harm as a result of the existing fibre technologies employed for blood oxygenation, the medical technology company said.
In present fibre oxygenators, blood is forced to travel in a detrimental turbulent flow through multiple layers of fibres while encountering friction and shear forces within the fibre walls, in contrast to the normal laminar blood flow found in blood arteries inside the body.
Due to the fibre fabric’s substantial resistance to blood flow, high-pressure differences arise and harm the different components of blood, such as high haemolysis, damage to white blood cells, immune system activation, inflammatory system activation, and blood clotting.
Inspira Technologies CEO Dagi Ben-Noon: “We believe that this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator of the INSPIRA ART500’s core technological portfolio.”
The INSPIRA ART500 is a ground-breaking device that continually measures the patient’s blood parameters in real-time. It is based on augmented respiration technology that rebalances patient oxygen saturation levels.
It is designed to inject the necessary volume of oxygen directly into the blood, empowering breathing in conscious patients.
The INSPIRA ART500, equipped with the HYLA blood sensor, is set to enable it to continually scan the patient’s blood.
This will also enable real-time detection of changes in the patient’s condition and offer doctors data that will aid in their decision-making, Inspira Technologies added.
